MedTrace Logo

Rifaximin Therapy in Chronic Kidney Disease

NCT02342639 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 38

Last updated 2021-11-05

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine if Rifaximin decreases serum and urine levels of bacterial byproducts and inflammatory markers in patients with chronic kidney disease and to evaluate changes in the bacterial content of the stool from these individuals.

Conditions

Interventions

DRUG

Rifaximin

550mg pills

DRUG

Placebo

Placebo pill

Sponsors & Collaborators

  • Jason Stubbs, MD

    lead OTHER

Principal Investigators

  • Jason Stubbs, MD · University of Kansas Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-06-30
Primary Completion
2019-03-01
Completion
2019-03-01

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02342639 on ClinicalTrials.gov